A newcomer to the EU, on the vaccine side.

The European Commission announced on Wednesday that it had entered into a contract with US pharmaceutical company Novavax for the advance purchase of 200 million doses of its vaccine once it has been approved by the European Medicines Agency (EMA).

"Our new agreement with Novavax expands our vaccine portfolio by adding another protein-based vaccine, a platform that has shown promise in clinical trials," Health Commissioner Stella Kyriakides said in a statement.

"Additional protection", for Ursula von der Leyen

Under the contract with Novavax, Member States will be able to purchase up to 100 million doses of the Novavax vaccine, with an option for an additional 100 million doses during the years 2021, 2022 and 2023, once it has been released. reviewed and approved by the EMA as safe and effective.

Member States will also be able to donate vaccines to low- and middle-income countries or redirect them to other European countries.

"As new variants spread in Europe and around the world, this new contract signed with a company which is already successfully testing its vaccine against these variants constitutes additional protection for our population", underlined the President of the Commission. Ursula von der Leyen.

The seventh contract of this type for the commission

For the Commission, which negotiates on behalf of the Twenty-Seven, this is the seventh contract of this type.

The EU has already concluded contracts with AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica (Johnson & Johnson), BioNtech-Pfizer, CureVac and Moderna, and it is in talks with the Franco-Austrian biotech Valneva.

The EU has already vaccinated 50% of its population, according to a count made by AFP, with vaccines from the companies BioNTech-Pfizer, Moderna, AstraZeneca and Johnson & Johnson, the only ones so far approved by the EMA.

A new contract was signed in early May with BioNTech-Pfizer for the purchase of 1.8 billion additional doses.

World

Coronavirus: WHO calls for a moratorium on booster doses until the end of September

Health

Vaccination: Does France also have an interest in offering a third dose against the Delta variant?


  • Health